EMAIL THIS PAGE TO A FRIEND

Pharmacology, biochemistry, and behavior

Valsartan reverses depressive/anxiety-like behavior and induces hippocampal neurogenesis and expression of BDNF protein in unpredictable chronic mild stress mice.


PMID 24844704

Abstract

Valsartan is a synthetic non-peptide angiotensin II type 1 receptor antagonist that dilates blood vessels and reduces blood pressure by blocking the action of angiotensin, and is safe and well tolerated in hypertensive patients. Population-based studies have suggested a positive role of sartans in reducing the risk of depression. This study aimed at investigating the effects of valsartan on unpredictable chronic mild stress (UCMS) mice by means of open-field test (OFT), novel-suppressed feeding test (NSF), tail suspension test (TST), forced swimming test (FST) and sucrose preference test (SPT). The effects of valsartan on antidepression/antianxiety, hippocampal neurogenesis and BDNF expression were evaluated in these behavior tests. Chronic administration of valsartan (5-40 mg/kg/d, p.o.) increased the time spent in the center of the field in OFT and the latency to eat in NSF, reduced the immobility time in both TST and FST, and increased the sucrose preference in SPT. A similar effect was observed in the positive control group of which the mice were treated with imipramine (30 mg/kg/d, i.p.) and tested by OFT, NSF, TST, FST and SPT. In this study, an impairment in hippocampal neurogenesis which parallelled with a reduced BDNF level in the hippocampus was observed in the mice that were treated with UCMS for 6 weeks. But the proliferation of progenitor cells and generation of new hippocampal neurons were restored after these mice were treated with valsartan (40 mg/kg/d, p.o.) for 4 weeks. These findings demonstrate that valsartan is an effective antidepressant/antianxiety reagent and can promote the hippocampal neurogenesis and expression of BDNF.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

AV41333
Anti-DCX (AB1) antibody produced in rabbit, affinity isolated antibody
AV41332
Anti-DCX (AB2) antibody produced in rabbit, affinity isolated antibody
SAB2502091
Anti-Dcx antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB2501666
Anti-DCX antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB1405701
Anti-DCX antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
D9943
Anti-Doublecortin (N-terminal) antibody produced in rabbit, ~1.5 mg/mL, affinity isolated antibody, buffered aqueous solution
D9693
Anti-Doublecortin antibody produced in rabbit, ~1 mg/mL, affinity isolated antibody, buffered aqueous solution
SAB4300697
Anti-Doublecortin antibody produced in rabbit, affinity isolated antibody
SAB4500628
Anti-Doublecortin antibody produced in rabbit, affinity isolated antibody
Y0000893
Imipramine for system suitability, European Pharmacopoeia (EP) Reference Standard
C19H24N2 · HCl
I0899
Imipramine hydrochloride, BioXtra, ≥99% (TLC)
C19H24N2 · HCl
I0100000
Imipramine hydrochloride, European Pharmacopoeia (EP) Reference Standard
C19H24N2 · HCl
1338007
Imipramine hydrochloride, United States Pharmacopeia (USP) Reference Standard
C19H24N2 · HCl
I7379
Imipramine hydrochloride, ≥99% (TLC)
C19H24N2 · HCl
I-902
Imipramine hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material
C19H24N2 · HCl
WH0001641M1
Monoclonal Anti-DCX antibody produced in mouse, clone 1G12, purified immunoglobulin, buffered aqueous solution
SAB1403727 Monoclonal Anti-DCX antibody produced in mouse, clone 3B7, purified immunoglobulin, buffered aqueous solution
Y0001132
Valsartan, European Pharmacopoeia (EP) Reference Standard
C24H29N5O3
1708762
Valsartan, United States Pharmacopeia (USP) Reference Standard
C24H29N5O3
SML0142
Valsartan, ≥98% (HPLC)
C24H29N5O3
PHR1315
Valsartan, Pharmaceutical Secondary Standard; Certified Reference Material
C24H29N5O3
Y0001131
Valsartan for peak identification, European Pharmacopoeia (EP) Reference Standard
C24H29N5O3
Y0001145
Valsartan for system suitability, European Pharmacopoeia (EP) Reference Standard
C24H29N5O3